Angiomax bivalirudin: Phase III data; marketed to treat unstable angina in patients undergoing angioplasty in the U.S. and New Zealand

MDCO said international Phase III data published in the American Heart Journal comparing Angiomax to heparin showed Angiomax reduced the risk of death, MI or urgent revascularization by 22% after 7 da...